Trial Profile

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Diphenhydramine (Primary) ; Diphenhydramine (Primary) ; Isatuximab (Primary) ; Methylprednisolone (Primary) ; Montelukast (Primary) ; Paracetamol (Primary) ; Paracetamol (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms SubQSA
Sponsors Sanofi

07 Mar 2025 Planned initiation date changed from 17 Feb 2025 to 31 Mar 2025.
07 Mar 2025 Status changed from not yet recruiting to recruiting.
04 Feb 2025 Planned initiation date changed from 30 Jan 2025 to 17 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com